VenoStent vs Revvity

Side-by-side comparison of AI visibility scores, market position, and capabilities

Revvity leads in AI visibility (94 vs 55)
VenoStent logo

VenoStent

ChallengerHealthcare

General

Houston TX YC W20 clinical-stage AV fistula wrap for dialysis patients with 200-patient RCT underway; $22.8M total ($20M Good Growth/Norwest Series A Jun 2024 + $3.6M NIH grant) targeting vascular access failure competing for dialysis market.

AI VisibilityBeta
Overall Score
C55
Category Rank
#144 of 1158
AI Consensus
54%
Trend
up
Per Platform
ChatGPT
51
Perplexity
55
Gemini
64

About

VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.

Full profile
Revvity logo

Revvity

LeaderHealthcare Tech

Life Science Tools & Diagnostics

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
A94
Category Rank
#1 of 1
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
92
Perplexity
99
Gemini
96

About

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Full profile

AI Visibility Head-to-Head

55
Overall Score
94
#144
Category Rank
#1
54
AI Consensus
72
up
Trend
up
51
ChatGPT
92
55
Perplexity
99
64
Gemini
96
66
Claude
89
49
Grok
88

Key Details

Category
General
Life Science Tools & Diagnostics
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Revvity
Life Science Tools & Diagnostics

Integrations

Only Revvity
Revvity is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.